AIMS: To investigate AT-rich interactive domain-containing protein 1A (ARID1A) and p53 expression in small intestinal carcinoma (SIC) and to determine its prognostic significance. METHODS AND RESULTS: Immunohistochemical staining for ARID1A and p53 was performed in 178 SICs using a tissue microarray (TMA). Loss of or low ARID1A expression was observed in 36 (20.2%) and 60 (33.7%) of cases, respectively. Aberrant p53 expression was observed in 99 (55.6%) cases. Loss of or low ARID1A expression was found to be associated with signet ring cell carcinoma and undifferentiated carcinoma, a high-grade tumour, and a higher T stage. No relationship was found between aberrant p53 expression and clinicopathological factors or overall survival. Patients with loss of ARID1A expression, irrespective of p53 expressional status, showed significantly poorer overall survival than those expressing ARID1A. Multiple regression analysis revealed that grade and pT stage were associated significantly with ARID1A loss, and multivariate analysis showed that patients with high ARID1A expression had a lower risk of death than those with loss of ARID1A expression. CONCLUSIONS: Low or loss of ARID1A expression is correlated significantly with a high-grade tumour, higher T stage, and poorer overall survival. These findings suggest that ARID1A expression could be used as a prognostic marker in SIC.
AIMS: To investigate AT-rich interactive domain-containing protein 1A (ARID1A) and p53 expression in small intestinal carcinoma (SIC) and to determine its prognostic significance. METHODS AND RESULTS: Immunohistochemical staining for ARID1A and p53 was performed in 178 SICs using a tissue microarray (TMA). Loss of or low ARID1A expression was observed in 36 (20.2%) and 60 (33.7%) of cases, respectively. Aberrant p53 expression was observed in 99 (55.6%) cases. Loss of or low ARID1A expression was found to be associated with signet ring cell carcinoma and undifferentiated carcinoma, a high-grade tumour, and a higher T stage. No relationship was found between aberrant p53 expression and clinicopathological factors or overall survival. Patients with loss of ARID1A expression, irrespective of p53 expressional status, showed significantly poorer overall survival than those expressing ARID1A. Multiple regression analysis revealed that grade and pT stage were associated significantly with ARID1A loss, and multivariate analysis showed that patients with high ARID1A expression had a lower risk of death than those with loss of ARID1A expression. CONCLUSIONS: Low or loss of ARID1A expression is correlated significantly with a high-grade tumour, higher T stage, and poorer overall survival. These findings suggest that ARID1A expression could be used as a prognostic marker in SIC.
Authors: Claudio Luchini; Nicola Veronese; Marco Solmi; Hanbyoul Cho; Jae-Hoon Kim; Angela Chou; Anthony J Gill; Sheila F Faraj; Alcides Chaux; George J Netto; Kentaro Nakayama; Satoru Kyo; Soo Young Lee; Duck-Woo Kim; George M Yousef; Andreas Scorilas; Gregg S Nelson; Martin Köbel; Steve E Kalloger; David F Schaeffer; Hai-Bo Yan; Feng Liu; Yoshihito Yokoyama; Xianyu Zhang; Da Pang; Zsuzsanna Lichner; Giuseppe Sergi; Enzo Manzato; Paola Capelli; Laura D Wood; Aldo Scarpa; Christoph U Correll Journal: Oncotarget Date: 2015-11-17
Authors: Hyun Deuk Cho; Jong Eun Lee; Hae Yoen Jung; Mee-Hye Oh; Ji-Hye Lee; Si-Hyong Jang; Kyung-Ju Kim; Sun Wook Han; Sung Yong Kim; Han Jo Kim; Sang Byung Bae; Hyun Ju Lee Journal: J Breast Cancer Date: 2015-12-23 Impact factor: 3.588